A cardiologist's view of hypoglycemia
Related Experiment Video
Updated: Jun 13, 2026

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice
Published on: January 26, 2024
Shailesh Nandish1, Jamison Wyatt, Rene Oliveros
1Cardiovascular Diseases, UT Health Science Center, San Antonio, TX, 78229-3900, USA. nandish@uthscsa.edu
Insights
Intensive diabetes treatment aiming for low glycated hemoglobin (A1c) did not improve cardiovascular outcomes, likely due to hypoglycemia. Review covers glucose metabolism, hypoglycemia risks, and diabetes drug impacts.
Area of Science:
- Endocrinology
- Cardiology
- Metabolic Research
Background:
- Intensive glycemic control (glycated hemoglobin [A1c] < 7.0%) has not demonstrated improved cardiovascular mortality in recent trials.
- Hypoglycemia, or low blood sugar, is a significant concern with aggressive glucose-lowering therapies.
- The failure to observe cardiovascular benefits may be linked to the adverse effects of frequent hypoglycemic episodes.
Purpose of the Study:
- To review the physiological basis of glucose metabolism.
- To examine the cardiovascular pathophysiology associated with hypoglycemia.
- To analyze clinical trials investigating intensive glucose-lowering strategies and their impact on microvascular and macrovascular complications.
Main Methods:
- Literature review of physiological mechanisms.
- Analysis of cardiovascular consequences of hypoglycemia.
- Examination of data from clinical trials on intensive diabetes management.
- Review of current non-insulin antidiabetic medications.
Main Results:
- Intensive glycemic control did not reduce cardiovascular mortality.
- Excessive hypoglycemia is implicated as a major factor limiting cardiovascular benefits.
- The review synthesizes information on glucose metabolism, hypoglycemia's cardiovascular effects, and trial outcomes.
Conclusions:
- Aggressive targets for glycated hemoglobin (A1c) may not confer cardiovascular benefits due to hypoglycemia risks.
- Understanding the interplay between glucose control, hypoglycemia, and cardiovascular health is crucial.
- Evaluation of non-insulin diabetes drugs should consider their hypoglycemic and cardiovascular profiles.
Abstract:
Recent studies have failed to show an improvement in cardiovascular mortality with intensive glycemic control and aggressive glycated hemoglobin (A(1c)) targets less than 7.0%. Excessive hypoglycemic episodes with intensive glucose-lowering therapy are thought to be a major factor in the failure to show cardiovascular benefit in these trials. In this article, we review the physiology of glucose metabolism, the cardiovascular pathophysiology of hypoglycemia, and the trials with an intensive glucose-lowering strategy that have studied microvascular and macrovascular complications. We also review the current non-insulin drugs available for the treatment of diabetes and their potential hypoglycemic and cardiovascular impacts.
Related Concept Videos
Hypoglycemia
Hypoglycemia and Glucagon
Hyperglycemia
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Symptoms, Diagnosis, and Complications

